DK3204386T3 - Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed - Google Patents
Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed Download PDFInfo
- Publication number
- DK3204386T3 DK3204386T3 DK15848476.6T DK15848476T DK3204386T3 DK 3204386 T3 DK3204386 T3 DK 3204386T3 DK 15848476 T DK15848476 T DK 15848476T DK 3204386 T3 DK3204386 T3 DK 3204386T3
- Authority
- DK
- Denmark
- Prior art keywords
- aminopury
- substituted
- compositions
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3204386T3 true DK3204386T3 (da) | 2021-05-25 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15848476.6T DK3204386T3 (da) | 2014-10-06 | 2015-10-05 | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (da) |
| EP (2) | EP3204386B1 (da) |
| JP (4) | JP6884701B2 (da) |
| KR (2) | KR102504849B1 (da) |
| CN (2) | CN113248506A (da) |
| AR (1) | AR102171A1 (da) |
| AU (2) | AU2015328414B2 (da) |
| CA (1) | CA2963639C (da) |
| CL (1) | CL2017000820A1 (da) |
| CO (1) | CO2017003838A2 (da) |
| CY (1) | CY1124173T1 (da) |
| DK (1) | DK3204386T3 (da) |
| EA (1) | EA201790779A1 (da) |
| EC (1) | ECSP17026210A (da) |
| ES (1) | ES2871142T3 (da) |
| HR (1) | HRP20210656T1 (da) |
| HU (1) | HUE054694T2 (da) |
| IL (2) | IL251566B (da) |
| LT (1) | LT3204386T (da) |
| MX (2) | MX2017004600A (da) |
| NZ (2) | NZ767954A (da) |
| PL (1) | PL3204386T3 (da) |
| PT (1) | PT3204386T (da) |
| RS (1) | RS61884B1 (da) |
| SG (2) | SG10202009598VA (da) |
| SI (1) | SI3204386T1 (da) |
| TW (1) | TW201629063A (da) |
| WO (1) | WO2016057370A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3204386T1 (sl) | 2014-10-06 | 2021-08-31 | Signal Pharmaceuticals, Llc | Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi |
| WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| CA2975260A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CA2980161A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
| EP3271361B1 (en) | 2015-03-18 | 2020-04-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
| EA032315B1 (ru) | 2015-03-18 | 2019-05-31 | Бристол-Маерс Сквибб Компани | Замещенные трициклические гетероциклические соединения |
| MX2018001004A (es) | 2015-07-24 | 2018-06-07 | Celgene Corp | Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este. |
| KR20180031773A (ko) | 2015-08-03 | 2018-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf 알파의 조정제로서 유용한 시클릭 화합물 |
| WO2017173206A1 (en) * | 2016-04-01 | 2017-10-05 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| RS62496B1 (sr) * | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu |
| JP6949057B2 (ja) | 2016-06-02 | 2021-10-13 | セルジーン コーポレイション | 動物及びヒトの抗トリパノソーマならびに抗リーシュマニア薬 |
| ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
| AU2018345647A1 (en) * | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| JP2020536100A (ja) * | 2017-10-04 | 2020-12-10 | セルジーン コーポレイション | シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| JP2009516707A (ja) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| CA2667345C (en) | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| ES2400006T3 (es) | 2008-04-23 | 2013-04-04 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| SI3204386T1 (sl) | 2014-10-06 | 2021-08-31 | Signal Pharmaceuticals, Llc | Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi |
| RS62496B1 (sr) | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu |
-
2015
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en active Application Filing
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 NZ NZ767954A patent/NZ767954A/en unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active IP Right Grant
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 MX MX2017004600A patent/MX2017004600A/es unknown
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko active Application Filing
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 NZ NZ730753A patent/NZ730753A/en unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-04-26 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3161124T3 (da) | Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3125927T3 (da) | Fremgangsmåder og sammensætninger til immunmodulering | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3119808T3 (da) | Antistofsammensætninger til tumorbehandling | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3157527T3 (da) | Ezh2-hæmmere til lymfombehandling | |
| DK3040326T3 (da) | Haloolefin-baseret sammensætning | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3353168T3 (da) | Forbindelser og fremgangsmåder til at inhibere jak | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3197890T3 (da) | Disubstituerede diaryloxybenzoheterodiazolforbindelser |